Black Forest Biologicals, a biotech startup, has a promising Alzheimer's drug candidate Compound SLT-88 entering Phase I trials this year. SLT-88 is the only product formed by the reaction of two precursor compounds A and B, both of which are quite expensive. The chief medicinal chemist of Black Forest is trying out different reaction conditions to minimize the cost of manufacturing SLT-88. In the table below are listed the initial and final amounts of A and B used under two different trial conditions, and also the actual amount of SLT-88 recovered in each case. Complete the table by calculating the theoretical yield of SLT-88 and the percent yield of SLT-88. Round your amounts to the nearest milligram and your percentages to the nearest whole percent